← Back to headlines
AstraZeneca Secures COPD Drug License from Sino Biopharmaceutical for $200M
AstraZeneca has agreed to pay $200 million upfront to Sino Biopharmaceutical for a licensing deal concerning a new chronic obstructive pulmonary disease (COPD) drug.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
